ClinicalTrials.gg
CompletedNCT01874678Updated Jan 12, 2016

A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer

An interventional study of TS-1/Cisplatin in Non-small-cell Lung Cancer (NSCLC), sponsored by TTY Biopharm. Completed at 5 sites in Taiwan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-01-12.

Sponsored by TTY Biopharm · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan — 96 open to participants now, 203 under way, 91 of them phase 3. Carcinoma, Non-Small-Cell Lung · Taiwan.

Enrollment
423rd of 479
45 · median 252
Started
2011
with 7 others
No phase
21 of 519
4 open now
Registered
121st of 519
by date

Among the 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan, this one is the 423rd largest by enrollment of the 479 interventional ones that give a count, is one of 8 that started in 2011, is one of 21 with no phase, and was the 121st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

96 of the 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan, or all of them as a file.
02

Study summary

Objectives:

  1. Primary Objective:

    To bridge the data of efficacy in term of overall response rate of TS-1 plus cisplatin in Taiwanese advanced NSCLC patients from that gained from Japanese population

  2. Secondary Objectives:

A. To assess progression free survival B. To assess overall survival C. To bridge the safety profile by assessing the toxicities and tolerability

03

Conditions studied

  • Non-small-cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for inclusion, each subject must fulfill all of the following criteria:

  1. or cytologically confirmed non-small cell bronchogenic carcinoma
  2. Stage IIIb or IV disease
  3. presence of at least one which is defined as lesion that can be measured in at least 1 dimension as ≥20 mm with conventional CT/MRI or ≥10 mm with spiral CT scan
  4. performance status of 0, 1
  5. age between 20 and 74 years at registration
  6. of at least 12 weeks
  7. ability to take the oral study medication (TS-1)
  8. voluntarily signed the written form.

Exclusion criteria

Exclusion Criteria:

  • other with the exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to the entry of study
  • previously received chemotherapy or therapy with systemic anti-tumor effect
  • significant co-morbid medical conditions, including, but not limited to , heart failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or paralytic ileus, or poorly controlled diabetes
  • fertile women of unless using a reliable and appropriate method throughout the treatment period and for three months following cessation of treatment
  • Presence of mental disease or psychotic manifestation
  • Participation in another clinical trial with any drug within 30 days prior to entry
  • judged ineligible by physicians for participation in the study due to safety concern.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    TS-1/Cisplatin

    single arm

    Drug: TS-1/Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. overall response rate

    To assess overall response rate

    Time frame: 2 year

Secondary outcomes

  1. To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability

    To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability

    Time frame: 2 year

07

Study locations

5 sites
  • Dalin Tzu Chi General Hospital
    Chiayi, Taiwan
  • E-Da Hospital
    Kaohsiung, Taiwan
  • China Medical University Hospital
    Taichung, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

References and documents

Publications

  • Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010 Dec 20;28(36):5240-6. doi: 10.1200/JCO.2010.31.0326. Epub 2010 Nov 15. PubMed 21079147 ↗
  • Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004 Dec 1;10(23):7860-4. doi: 10.1158/1078-0432.CCR-04-1200. PubMed 15585618 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2013
First posted
Jun 11, 2013
Start
Mar 2011
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Jan 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01874678
Lead sponsor
TTY Biopharm
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
Mar 2011
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Jan 12, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid · Cisplatin

Start the discussion